Clinical Trial: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Brief Summary: This research trial studies genes in tissue samples from younger and adolescent patients with soft tissue sarcomas. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer

Detailed Summary:

Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Tissue Study Population Description: Existing NRSTS samples from the COG D9902/ARST0332 studies Sampling Method: Non-Probability Sample

OBJECTIVES:

I. To determine the frequency with which actionable mutations are found in archived non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) tumor specimens using mass spectrometry (MS) analysis of tumor-derived deoxyribonucleic acid (DNA).

OUTLINE:

Archived DNA tissue samples are analyzed for frequency of genetic mutations, including single nucleotide polymorphisms (SNPs), single nucleotide variants (SNVs), and small deletions and/or insertions, by polymerase chain reaction (PCR) and mass spectometry (Sequenom MassARRAY). Results are then analyzed to determine whether specific mutations correlate with patient or disease features such as tumor stage, histological grade, or outcome.


Sponsor: Children's Oncology Group

Current Primary Outcome:

  • Frequency of individual mutated genes in patients with NRSTS [ Time Frame: Up to 1 month ]
  • Genetic changes that are most common and likely to have the greatest therapeutic impact [ Time Frame: Up to 1 month ]


Original Primary Outcome:

  • Frequency of individual mutated genes in patients with NRSTS
  • Genetic changes that are most common and likely to have the greatest therapeutic impact


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Children's Oncology Group

Dates:
Date Received: March 27, 2012
Date Started: May 2016
Date Completion:
Last Updated: May 13, 2016
Last Verified: May 2016